TG Therapeutics Raises Guidance as BRIUMVI's Momentum Fuels Broader Ambition

NEW YORK, NY – August 03, 2026 – TG Therapeutics (NASDAQ: TGTX) delivered a powerful growth signal to the market today, reporting second-quarter financial results that dramatically outpaced expectations and prompted a significant upward revision of its full-year revenue guidance. The performance is fueled by the explosive commercial success of its multiple sclerosis (MS) drug, BRIUMVI, which is not only capturing significant market share but is also funding an ambitious strategic pivot for the company.

In a statement accompanying the results, Chairman and CEO Michael S. Weiss captured the buoyant mood, declaring the quarter “another strong quarter for TG Therapeutics.” He noted that BRIUMVI’s outstanding commercial performance has put the company “on track to exit 2026 at an approximately $1 billion annualized U.S. BRIUMVI revenue run rate.” This is more than just a financial milestone; it’s the foundation upon which the biotech is building a much broader future.

A Signal of Financial Strength

The numbers speak for themselves. The New York-based company announced total global revenues of approximately $240 million for the second quarter, with U.S. net sales of BRIUMVI contributing a staggering $227.7 million. This represents a remarkable 64% increase over the same period last year, a clear indicator of accelerating adoption by physicians and patients.

This robust performance led the company to confidently raise its full-year 2026 financial targets. It now projects total global revenue to reach approximately $950 million, with U.S. BRIUMVI sales expected to land between $890 million and $905 million. This bullish forecast, an increase from guidance issued just last quarter, reflects a deep-seated confidence in BRIUMVI's market trajectory.

Wall Street has taken notice. While the MS market is dominated by behemoths like Roche, whose drug Ocrevus remains a multi-billion-dollar franchise, BRIUMVI is carving out a significant niche. The stock has seen a surge of over 75% year-to-date, with investors rewarding the consistent revenue growth and expanding pipeline. Recent price target increases from analysts at firms like HC Wainwright and Jefferies Financial Group underscore a growing consensus that TG Therapeutics is successfully executing its commercial strategy. The company's ability to generate net income of $7.8 million for the quarter while heavily investing in R&D further demonstrates its strengthening financial discipline and the powerful leverage of its lead product.

Redefining Convenience in MS Treatment

BRIUMVI’s success isn't just about effective marketing; it's rooted in clinical differentiation. As the third anti-CD20 antibody approved for relapsing forms of multiple sclerosis (RMS), it entered a competitive field. However, the company has focused on a key pain point for patients and providers: treatment burden.

A pivotal development is the positive topline data from the Phase 3 ENHANCE trial. The study successfully demonstrated that BRIUMVI's two-part initiation infusion—currently given on Day 1 and Day 15—can be consolidated into a single, slightly longer infusion on Day 1. This seemingly simple change is a significant logistical and psychological win, eliminating an entire clinic visit for patients beginning therapy. If approved by the FDA, this simplified regimen would be a first for an IV anti-CD20 therapy and could further accelerate BRIUMVI's adoption by offering unparalleled convenience for an infused therapy.

This focus on patient experience is a core part of the company's strategy. With over 25,000 patients prescribed the drug globally as of the first quarter, the momentum is tangible. The combination of strong efficacy, a favorable safety profile, and now the prospect of a more convenient initiation is proving to be a potent formula for market penetration.

Building a Pipeline Beyond Multiple Sclerosis

Perhaps the most telling signal of TG Therapeutics' long-term ambition is how it is deploying the capital generated by BRIUMVI. The company is strategically transforming from an MS-focused entity into a diversified player targeting a range of immune-mediated diseases. As Mr. Weiss stated, “As BRIUMVI continues to grow, it is becoming the foundation of a broader company focused on advancing innovative therapies for immune-mediated diseases.”

Two major initiatives highlight this evolution. First is the development of a subcutaneous (under-the-skin) formulation of BRIUMVI. Following positive Phase 1 data, a pivotal Phase 3 trial is fully enrolled, with topline results expected by early 2027. A subcutaneous version would be a game-changer, allowing for at-home administration and directly competing with other self-injected therapies. The company is backing this move with a substantial $100 million investment in manufacturing and start-up costs, signaling its commitment to bringing this next-generation version to market.

Second, the company is boldly expanding into entirely new therapeutic areas. It has initiated a Phase 2 trial of BRIUMVI in Myasthenia Gravis (MG), a chronic autoimmune disorder that causes muscle weakness. This move into a market estimated to be worth over $6 billion positions BRIUMVI in a new high-need area. Even more audacious is the recent initiation of a Phase 2 trial for treatment-resistant schizophrenia. This high-risk, high-reward program is based on emerging evidence linking neuroinflammation to psychiatric disorders and represents a pioneering effort to apply B-cell depletion in a field desperate for new mechanisms of action.

From Niche Player to Diversified Innovator

TG Therapeutics is executing a classic biotech growth strategy: establish a beachhead with a successful commercial product and use its revenue stream to fund a pipeline of next-generation assets and exploratory programs. The company’s rising R&D and SG&A expenses, which totaled over $177 million in the quarter, are not signs of bloat but rather the fuel for this expansion. These are the calculated investments required to run pivotal trials, scale up manufacturing for a new formulation, and launch commercial efforts in new territories and indications.

By leveraging BRIUMVI's commercial momentum, the company has secured a strong cash position of over $612 million and projects that its current assets, combined with future revenue, are sufficient to fund its ambitious operating plan. This financial independence allows it to pursue a multi-pronged strategy aimed at maximizing the value of its lead asset while simultaneously de-risking its future with a diversified pipeline. The progress made this quarter reinforces a clear signal: TG Therapeutics is no longer just an MS company; it is building a fully integrated immunology powerhouse, and potentially neurology, powerhouse.